Seattle, WA , April 17, 2018 (GLOBE NEWSWIRE) -- Apotheca Biosciences (PCFP), a developer of cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry announces today that the company has developed three core platform technologies; CannaRAPID™, CannaNASAL™, and CannaDERME™, focused on precise dosing and controlled release of cannabinoid compounds for patients. Apotheca announces today that the Company’s 2018 R & D goals focused on products and technologies to address opioid crisis.
On October 26, 2017, US Government directed the Department of Health and Human Services to declare the opioid crisis a public health emergency, taking long-anticipated action to address a rapidly escalating epidemic of drug use. United States is in the middle of an unprecedented opioid epidemic; Since 2000, the rate of overdose deaths involving opioids nearly quadrupled, and over 165,000 people have died from prescription opioid overdoses. Prevention, treatment, and research to rapidly tackle and reverse opioid overdoses are critical to fighting this epidemic.
Studies have shown that phyto-cannabinoids like Cannabidiol have promising results in opioid withdrawal symptoms and heroin-seeking behavior. Apotheca’s studies have shown that Cannabidiol can have promising improvements in opioid withdrawal symptoms by attenuating the rewarding effects of opioids. Apotheca has been developing various cannabinoid delivery technologies and state-of-the art smart medical devices for relieving various pains and opioid withdrawal symptoms. There is strong evidence that cannabinoid compounds can relieve from depression caused by drug addiction. Apotheca is partnering with opioid addiction centers and clinical practitioners to conduct studies on the use of PainPatch for opioid addiction.
“Data is showing that on an average day in US about 140 people die from an opioid-related overdose, most of the ones died belongs to the younger population” said Bobban Subhadra, M.S., Ph.D, Chief Executive Officer of Apotheca. “This is a serious epidemic that need to be dealt with a high level of urgency; we are talking about teens who are the future of our nation dying in high numbers on our streets. That is the reason, why we at Apotheca, wanted to seriously invest in the application of our PainPatch as a possible intervention for opioid addiction. Even if we can save one young life with our technology, we will take it as an enormous success” he added.
Apotheca Biosciences is developing cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry. Their pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids.
Apotheca Biosciences is a pioneering biotech company with an emphasis in research and development in addition to the creation of high-grade nutraceuticals and cosmetics. Apothecia’s’ goal is to lay the groundwork and continue research of cannabinoid receptiveness in patients and create nutraceuticals that reflects their research.
More information on Apotheca Biosciences can be found at: http://www.apothecabiosciences.com/
About Apotheca Biosciences
Apotheca Biosciences is a developer of cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry. Our pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids. We believe that we can deliver meaningful benefits using our technologies to the world’s aging population.
To request further information about Apotheca, please email us at info@apothecabiosciences.com, log onto our website at http://www.apothecabiosciences.com/, or visit us on FB @apotheca and Twitter @apotheca
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.